EAGAN, Minn.--(BUSINESS WIRE)--Biothera has named Robert C. Shepard, M.D., F.A.C.P. as Chief Medical Officer with responsibility for overseeing the clinical development of Imprime PGG®, the company’s targeted immunotherapeutic drug that works synergistically with monoclonal antibodies in the treatment of a wide range of cancers, including colorectal and lung cancer.
